Abstracts tagged "autoantibodies"

Abstract Number: 292 • 2012 ACR/ARHP Annual Meeting
Clinical Utility of Anti-CADM-140/Melanoma Differentiation-Associated Gene 5 Autoantibody Titers in Patients with Juvenile Dermatomyositis and Rapidly Progressive Interstitial Lung Disease
Shinji Sato¹, Norimoto Kobayashi², Kazuko Yamazaki³ and Yasuo Suzuki⁴, ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan, ³Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: The presence of anti-CADM-140/ (Melanoma Differentiation-Associated Gene 5: MDA5) autoantibody is specific for adult dermatomyositis (DM), especially in patients with little or no muscle…
Abstract Number: 1776 • 2012 ACR/ARHP Annual Meeting
Anti-SSA/Ro Mediated Injury to the Endothelium Via Urokinase Plasminogen Activator Receptor/Tgfbeta Activation: Implications in the Pathogenesis of Congenital Heart Block
Paraskevi Briasouli¹, Mark Halushka², Jill P. Buyon³ and Robert M. Clancy⁴, ¹Rheumatology, New York University Medical Center, New York, NY, ²Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: One mechanism by which anti-Ro antibodies are linked to the pathogenesis of (cardiac-NL) neonatal lupus is the increased urokinase plasminogen activator (uPA)/urokinase-type plasminogen activator receptor…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
Abstract Number: 277 • 2012 ACR/ARHP Annual Meeting
Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Katia T. Kozu¹, Clovis Artur Silva², Eloisa Bonfa³, Adriana M. Sallum⁴, Rosa M.R. Pereira⁵, Vilma S. Viana⁶, Eduardo F. Borba⁷ and Lucia M. A. Campos⁴, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Dyslipidemia has been infrequently investigated in pediatric population with autoimmune rheumatic diseases. However, lipid abnormalities in these diseases may occur due to multiple risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].